Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.95 |
| ▸ | CPT2 | P23786 | 1/20 | 0.95 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037104 | 1.00 | ACLY (0.95) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL6908482 | 1.00 | ACLY (0.95) | ACLYCPT2HSPD1BLMHSPE1 | |
| Water SCHEMBL2964489 | 0.98 | ACLY (0.91) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL2817674 | 0.98 | ACLY (0.91) | ACLYCPT2HSPD1BLMHSPE1 | |
| Water SCHEMBL2956336 | 0.98 | ACLY (0.91) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL17181773 | 0.98 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL2111332 | 0.98 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL17181757 | 0.98 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL6773065 | 0.98 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL2110910 | 0.98 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118726256-A | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-10-01 | — | — | CN | disclosed |
| CN-112262212-B | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-07-12 | — | — | CN | disclosed |
| US-20210071141-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-03-11 | — | — | US | disclosed |
| CN-112262212-A | Methods of generating T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2021-01-22 | — | — | CN | disclosed |
| US-7772428-B2 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | Northern Innovations and Formulations (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | NEW CELL FORMULATIONS LTD (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1846368-A4 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW HC FORMULATIONS LTD (CA) | 2008-01-23 | — | — | EP | disclosed |
| EP-1846368-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | New HC Formulations Ltd. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-31 | — | — | US | disclosed |
| WO-2006081682-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | CKMT1A; CKMT1B, GYS1, PYGM | ACLY 62/4885CPT2 152/4885HSPD1 251/4885 |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | CKMT1A; CKMT1B, GYS1, PYGM | ACLY 62/4885CPT2 152/4885HSPD1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.